Overview
Development / Products in the Pipeline
Medical Network
Pharmaceutical Industry
Overview
1.1 MiLOC Biotechnology Limited -
research and development of TCM Drugs
MiLOC Biotechnology will be principally engaged in the
research and development of TCM drugs in the area of pandemic diseases.
MiLOC Biotechnology will, through its wholly owned
subsidiary, Smart Falcon, indirectly own the TCM IP Rights of Rorrico
(including the beneficial interest in the Patent Application). Rorrico
is a TCM drug developed for the treatment and prevention of influenza.
MiLOC Biotechnology is actively seeking opportunities to acquire other
TCM drug formulas for pandemic diseases.
1.2 MiLOC Pharmaceutical Limited - sales and
distribution of TCM Drugs
MiLOC
Pharmaceutical will carry out the sales and
distribution function of the Group’s TCM products, focusing initially on
China, Hong Kong and Macau with a view to broadly extending its sales
network throughout South East Asia It also intends to distribute TCM
drugs and health supplements from other TCM pharmaceutical companies.
1.3 MiLOC Medical Limited - operation of
mdernized TCM clinics and hospitals
MiLOC Medical intends to form various
joint ventures to acquire TCM Clinics and Hospitals in Hong
Kong, Macau and the PRC in the four years following Admission, building
a network of modernised TCM Clinics and Hospitals.
1.4 Smart Falcon
Smart Falcon is the holding company of the TCM IP Rights in relation to
Rorrico, (including the beneficial interest in the Patent Application).
Professor He Zhong Sheng is engaged by the Group as a Senior Consultant
(Scientist) to advise the Group on certain matters concerning Rorrico,
including manufacturing processes and quality.
2. Business strategy and objectives
The overall aim of the Group is to
explore the potential of TCM by introducing reliable TCM drugs to the
market, focusing initially on Hong Kong, the PRC and Macau with a view
to further expansion in South East Asia, and providing high quality
modernised TCM healthcare services in Hong Kong, Macau and the PRC. The
Group intends to promote a vertically-integrated TCM medical network
from primary care to tertiary care and market its healthcare services
and TCM products under a universal brand “MiLOC”.
There are two key elements underpinning this strategy:
(i) Developing reliable TCM drugs worldwide for
epidemic diseases
The Group’s objective is to bring effective and reliable TCM drugs to
the global market using modern drug research and development
technologies, including conducting clinical trials on the Group’s TCM
products. The Group will focus on the development of TCM drugs which are
expected to be significant to latest medical needs, particularly
influenza and other epidemic diseases.
(ii) Development of a nationwide network of
high quality modernized TCM clinics and hospitals in the PRC, Hong Kong
and Macau
MiLOC's strategy is to generate revenue as a TCM health care
service provider while leveraging the opportunity to distribute the
Group’s TCM products primarily through these target customers as a
pharmaceutical company, thereby diversifying the sources of revenue of
the Group and reducing marketing and administrative costs.
